Skip to content
OpenCapital
Get started

AbCellera Biologics Inc. ABCL EV / sales

EV / sales at other companies

Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
7.1×+0.7×
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
15.7×-13.3×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
5.8×+1.4×
Precigen logo
PrecigenPGEN
102.1×—
Zymeworks logo
ZymeworksZYME
20.1×+11.8×
ADMA Biologics logo
ADMA BiologicsADMA
4.3×-5.8×

Other financials

Income statement

See full
Revenue$8.3M+96.3%
Operating income-$57.5M+8.2%
Net income-$43.2M+5.4%
EPS (diluted)-$0.14+6.7%

Balance sheet

See full
Cash & equivalents$102.1M-44.6%
Total debt$140.2M+107%
Total equity$938.1M-8.3%
Total assets$1.3B-2.8%

Cash flow

See full
Operating cash flow-$33.5M-190%
CapEx$3.8M-64.0%
Free cash flow-$37.4M-68.3%

Valuation

See full
Market cap$1.84B+59.2%

Profitability

See full
Operating margin-267.6%-120pp
Net margin-181.7%-77.9pp
FCF margin-238.9%-90.9pp

Returns & leverage

See full
Return on equity-14.7%-0.8pp
Debt / equity0.1×+0.1×
Current ratio14.1×+3.9×

Where this comes from

Calculated from AbCellera Biologics Inc.’s reported figures.

enterprise value/total revenue=13.8×

Based on the most recent quarter.

The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbCellera Biologics Inc.'s ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbCellera Biologics Inc.'s EV / sales?
AbCellera Biologics Inc. (ABCL) reported EV / sales of 13.8× in Q1 2026.
How has AbCellera Biologics Inc.'s EV / sales changed year-over-year?
AbCellera Biologics Inc.'s EV / sales decreased by 41.6% year-over-year, from 23.7× to 13.8×.
What is the long-term trend for AbCellera Biologics Inc.'s EV / sales?
Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s EV / sales has grown at a -21.4% compound annual growth rate (CAGR), from 46.1× to 13.8×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.